Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of DXP604 in mild to moderate COVID-19
ChiCTR2200060096Phase 2Recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DXP-604 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoints: SARS-CoV-2 viral load in nasopharyngeal swabs, Adverse events and serious adverse events and 3 more. Started May 2022; status: recruiting.
02
Drugs
DXP-604
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060096.